Characteristic/ Study ID (trial identifier)	Endpoint	Time of measurement
Ludvik 2002	Glycaemic control (P)	0, 1.5 months
	Serum insulin, C‐peptide or insulin sensitivity (S)	0, 1.5 months
	Serum cholesterol (S)	0, 1.5 months
	Weight (S)	0, 1.5 months
	Adverse events (O)	0, 1.5 months
Ludvik 2004	Glycaemic control (P)	0, 2, 3 months
	Serum cholesterol and triglyceride (S)	0, 2, 3 months
	Adverse events (O)	0, 2, 3 months
Ludvik 2008	Glycaemic control (P)	0, 5 months
	Serum cholesterol and triglyceride (S)	0, 5 months
	Adverse events (O)	0, 5 months
Footnotes aEndpoint in bold/italic = review's primary/secondary outcome b(P) Primary or (S) secondary endpoint(s) refer to verbatim statements in the publication, (O) other endpoints relate to outcomes that were not specified as 'primary' or 'secondary' outcomes in the report